{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:16:58Z","timestamp":1794014218679,"version":"4.8.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T00:00:00Z","timestamp":1679616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011094","name":"Public Health Agency of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011094","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["202011FBD-457278-253354"],"award-info":[{"award-number":["202011FBD-457278-253354"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["NPC-178912"],"award-info":[{"award-number":["NPC-178912"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Americas"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.lana.2023.100490","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T05:54:01Z","timestamp":1684302841000},"page":"100490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Rapid hepatitis C virus point-of-care RNA testing and treatment at an integrated supervised consumption service in Toronto, Canada: a prospective, observational cohort study"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6186-0029","authenticated-orcid":false,"given":"Bernadette","family":"Lettner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zo\u00eb R.","family":"Greenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Broad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Mandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan J.","family":"Feld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Powis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lana.2023.100490_bib1","author":"World Health Organization"},{"issue":"19","key":"10.1016\/j.lana.2023.100490_bib2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.14745\/ccdr.v40i19a02","article-title":"Estimated prevalence of hepatitis C virus infection in Canada, 2011","volume":"40","author":"Trubnikov","year":"2014","journal-title":"Can Commun Dis Rep"},{"issue":"5","key":"10.1016\/j.lana.2023.100490_bib3","doi-asserted-by":"crossref","first-page":"138","DOI":"10.14745\/ccdr.v46i05a07","article-title":"National findings from the Tracks survey of people who inject drugs in Canada, Phase 4, 2017-2019","volume":"46","author":"Tarasuk","year":"2020","journal-title":"Can Commun Dis Rep"},{"key":"10.1016\/j.lana.2023.100490_bib4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/IJGM.S127689","article-title":"Hepatitis C treatment: where are we now?","volume":"10","author":"Burstow","year":"2017","journal-title":"Int J Gen Med"},{"issue":"12","key":"10.1016\/j.lana.2023.100490_bib5","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1111\/liv.14227","article-title":"The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: impact of direct acting antivirals","volume":"39","author":"Bartlett","year":"2019","journal-title":"Liver Int"},{"issue":"8","key":"10.1016\/j.lana.2023.100490_bib6","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/liv.14043","article-title":"Disparities in uptake of direct-acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting","volume":"39","author":"Soc\u00edas","year":"2019","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.lana.2023.100490_bib7","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/08897077.2018.1485128","article-title":"Hepatitis C cascade of care among people who inject drugs in Vancouver, Canada","volume":"39","author":"Young","year":"2018","journal-title":"Subst Abuse"},{"issue":"11","key":"10.1016\/j.lana.2023.100490_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0207226","article-title":"Beyond interferon side effects: what residual barriers exist to DAA hepatitis C treatment for people who inject drugs?","volume":"13","author":"Madden","year":"2018","journal-title":"PLoS One"},{"issue":"Suppl 2","key":"10.1016\/j.lana.2023.100490_bib9","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1093\/cid\/cit263","article-title":"Understanding barriers to hepatitis C virus care and stigmatization from a social perspective","volume":"57","author":"Treloar","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.lana.2023.100490_bib10","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1111\/liv.14469","article-title":"Frequent loss to follow-up after diagnosis of hepatitis C virus infection: a barrier towards the elimination of hepatitis C virus","volume":"40","author":"Aleman","year":"2020","journal-title":"Liver Int"},{"issue":"12","key":"10.1016\/j.lana.2023.100490_bib11","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1080\/14737159.2017.1400385","article-title":"Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis","volume":"17","author":"Grebely","year":"2017","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.lana.2023.100490_bib12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.drugpo.2018.08.011","article-title":"Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia","volume":"61","author":"Bajis","year":"2018","journal-title":"Int J Drug Policy"},{"issue":"4","key":"10.1016\/j.lana.2023.100490_bib13","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofv162","article-title":"Simultaneous human immunodeficiency virus-hepatitis B-hepatitis C point-of-care tests improve outcomes in linkage-to-care: results of a randomized control trial in persons without healthcare coverage","volume":"2","author":"Bottero","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.lana.2023.100490_bib14","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/528904","article-title":"Successful integration of hepatitis C virus point-of-care tests into the Denver metro health clinic","author":"Jewett","year":"2013","journal-title":"AIDS Res Treat"},{"issue":"7","key":"10.1016\/j.lana.2023.100490_bib15","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/jvh.13087","article-title":"Community-based, point-of-care hepatitis C testing: perspectives and preferences of people who inject drugs","volume":"26","author":"Latham","year":"2019","journal-title":"J\u00a0Viral Hepat"},{"issue":"2","key":"10.1016\/j.lana.2023.100490_bib16","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3138\/canlivj.1.2.002","article-title":"Diagnosis and treatment of hepatitis C virus infection: a tool for engagement with people who inject drugs in Vancouver's Downtown Eastside","volume":"1","author":"Alimohammadi","year":"2018","journal-title":"Can Liver J"},{"key":"10.1016\/j.lana.2023.100490_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102755","article-title":"Peer outreach point-of-care testing as a bridge to hepatitis C care for people who inject drugs in Toronto, Canada","volume":"80","author":"Broad","year":"2020","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.lana.2023.100490_bib18","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.drugalcdep.2014.10.012","article-title":"Supervised injection services: what has been demonstrated? A systematic literature review","volume":"145","author":"Potier","year":"2014","journal-title":"Drug Alcohol Depend"},{"issue":"9","key":"10.1016\/j.lana.2023.100490_bib20","article-title":"Drug consumption rooms (DCRs) as a setting to address hepatitis C - findings from an international online survey","volume":"3","author":"Belackova","year":"2018","journal-title":"Hepatol Med Policy"},{"issue":"4","key":"10.1016\/j.lana.2023.100490_bib21","first-page":"538","article-title":"The Ontario integrated supervised injection services cohort study of people who inject drugs in Toronto, Canada (OiSIS-Toronto): cohort profile","volume":"98","author":"Scheim","year":"2021","journal-title":"J\u00a0Urban Health"},{"key":"10.1016\/j.lana.2023.100490_bib22","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.drugpo.2017.05.025","article-title":"Understanding real-world adherence in the directly acting antiviral era: a prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada","volume":"47","author":"Mason","year":"2017","journal-title":"Int J Drug Policy"},{"issue":"12","key":"10.1016\/j.lana.2023.100490_bib23","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1093\/infdis\/jiy114","article-title":"Evaluation of the Xpert HCV viral load finger-stick point-of-care assay","volume":"217","author":"Lamoury","year":"2018","journal-title":"J\u00a0Infect Dis"},{"issue":"6","key":"10.1016\/j.lana.2023.100490_bib24","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.amepre.2020.01.024","article-title":"Harm reduction coverage and hepatitis C incidence: findings from a cohort of people who inject drugs","volume":"58","author":"Minoyan","year":"2020","journal-title":"Am J Prev Med"},{"issue":"2","key":"10.1016\/j.lana.2023.100490_bib25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/jvh.12628","article-title":"Higher incidence of HCV in females compared to males who inject drugs: a systematic review and meta-analysis","volume":"24","author":"Esmaeili","year":"2017","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.lana.2023.100490_bib27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jsat.2019.01.021","article-title":"Barriers and facilitators of hepatitis C treatment uptake among people who inject drugs enrolled in opioid treatment programs in Baltimore","volume":"100","author":"Falade-Nwulia","year":"2019","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"5","key":"10.1016\/j.lana.2023.100490_bib28","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/jvh.13664","article-title":"The impact of point-of-care hepatitis C testing in needle and syringe exchange programs on linkage to care and treatment uptake among people who inject drugs: an Australian pilot study","volume":"29","author":"Howell","year":"2022","journal-title":"J\u00a0Viral Hepat"},{"issue":"2","key":"10.1016\/j.lana.2023.100490_bib29","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/jvh.13780","article-title":"Integrated supervised consumption services and hepatitis C testing and treatment among people who inject drugs in Toronto, Canada: a cross-sectional analysis","volume":"30","author":"Greenwald","year":"2023","journal-title":"J\u00a0Viral Hepat"},{"issue":"4","key":"10.1016\/j.lana.2023.100490_bib30","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1016\/S2214-109X(20)30505-2","article-title":"Decentralisation, integration, and task-shifting in hepatitis C virus infection testing and treatment: a global systematic review and meta-analysis","volume":"9","author":"Oru","year":"2021","journal-title":"Lancet Global Health"},{"issue":"Suppl 2","key":"10.1016\/j.lana.2023.100490_bib31","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1093\/cid\/cit297","article-title":"Peer support models for people with a history of injecting drug use undertaking assessment and treatment for hepatitis C virus infection","volume":"57","author":"Crawford","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.lana.2023.100490_bib32","article-title":"Elimination of HCV as a public health concern among people who inject drugs by 2030 - what will it take to get there?","volume":"20","author":"Grebely","year":"2017","journal-title":"J\u00a0Int AIDS Soc"}],"container-title":["The Lancet Regional Health - Americas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667193X23000649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667193X23000649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:54:18Z","timestamp":1762642458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667193X23000649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":30,"alternative-id":["S2667193X23000649"],"URL":"https:\/\/doi.org\/10.1016\/j.lana.2023.100490","relation":{},"ISSN":["2667-193X"],"issn-type":[{"value":"2667-193X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rapid hepatitis C virus point-of-care RNA testing and treatment at an integrated supervised consumption service in Toronto, Canada: a prospective, observational cohort study","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Americas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lana.2023.100490","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100490"}}